Evidence map›Paper›PMID 33505314›Full record

ArticleFrontiers in pharmacology2020

Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing.

Chan Gyu Lee, TaeEun Kim, Sungyoul Hong, Jongwan Chu, Ju Eun Kang, Hee Geon Park, Jun Young Choi, Kyoung Song, Sun Young Rha, Soohyeon Lee and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Chan Gyu LeeLaboratory of Molecular Pathology and Cancer Genomics, College of Pharmacy, Seoul National University, Seoul, South Korea.
TaeEun KimLaboratory of Molecular Pathology and Cancer Genomics, College of Pharmacy, Seoul National University, Seoul, South Korea.
Sungyoul HongLaboratory of Molecular Pathology and Cancer Genomics, College of Pharmacy, Seoul National University, Seoul, South Korea.
Jongwan ChuLaboratory of Molecular Pathology and Cancer Genomics, College of Pharmacy, Seoul National University, Seoul, South Korea.
Ju Eun KangGenopharm Inc., Seoul, South Korea.
Hee Geon ParkDepartment of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, South Korea.
Jun Young ChoiR&D Center, ABION Inc., Seoul, South Korea.
Kyoung SongCollege of Pharmacy, Duksung Women's University, Seoul, South Korea.
Sun Young RhaYonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Soohyeon LeeDivision of Oncology-Hematology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.
Joon-Seok ChoiCollege of Pharmacy, Daegu Catholic University, Gyeongsan, South Korea.
Sun Min KimDepartment of Obstetrics and Gynecology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, and Seoul National University College of Medicine, Seoul, South Korea.
Hae Min JeongGenopharm Inc., Seoul, South Korea.
Young Kee ShinLaboratory of Molecular Pathology and Cancer Genomics, College of Pharmacy, Seoul National University, Seoul, South Korea.
Seoul National University · KRDaegu Catholic University · KRDuksung Women's University · KRKorea University · KRSNUH SMG-SNU Boramae Medical Center · KRYonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type I interferon (IFN) has been approved as an anticancer agent to treat some malignancies. However, IFNs have a short

Indexed as

HER2immune cell-mediated cytotoxicityimmunocytokineinterferon-beta muteintrastuzumabtumor-targeting

Identifiers

PMID33505314
PMCPMC7832035
OpenAlexW3120513004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.